Insider Selling: Avalo Therapeutics (NASDAQ:AVTX) CFO Sells $136,857.00 in Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) CFO Christopher Ryan Sullivan sold 7,980 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $17.15, for a total transaction of $136,857.00. Following the transaction, the chief financial officer directly owned 17,338 shares in the company, valued at $297,346.70. This represents a 31.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Ryan Sullivan also recently made the following trade(s):

• On Wednesday, April 1st, Christopher Ryan Sullivan sold 7,979 shares of Avalo Therapeutics stock. The shares were sold at an average price of $16.77, for a total value of $133,807.83.

Avalo Therapeutics Price Performance

Shares of NASDAQ:AVTX opened at $17.76 on Monday. The business’s 50 day simple moving average is $15.54 and its 200 day simple moving average is $16.04. Avalo Therapeutics, Inc. has a 1 year low of $3.39 and a 1 year high of $20.72. The company has a market capitalization of $404.75 million, a P/E ratio of -3.10 and a beta of 0.93.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings data on Monday, March 23rd. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($1.54) by $1.17. The company had revenue of $0.06 million during the quarter, compared to analyst estimates of ($0.21) million. On average, sell-side analysts anticipate that Avalo Therapeutics, Inc. will post -19.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Wall Street Zen raised shares of Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday, March 29th. BTIG Research restated a “buy” rating and issued a $40.00 target price on shares of Avalo Therapeutics in a research report on Tuesday, March 24th. Mizuho raised shares of Avalo Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Friday, January 9th. Finally, Guggenheim assumed coverage on shares of Avalo Therapeutics in a research note on Monday, February 2nd. They issued a “buy” rating and a $50.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $42.25.

Institutional Investors Weigh In On Avalo Therapeutics

Hedge funds have recently made changes to their positions in the stock. Seven Fleet Capital Management LP bought a new stake in shares of Avalo Therapeutics during the 4th quarter valued at approximately $1,150,000. XTX Topco Ltd lifted its stake in Avalo Therapeutics by 190.0% in the 4th quarter. XTX Topco Ltd now owns 40,458 shares of the company’s stock valued at $735,000 after purchasing an additional 26,508 shares during the last quarter. Squadron Capital Management LLC acquired a new stake in Avalo Therapeutics in the fourth quarter valued at approximately $2,361,000. SummitTX Capital L.P. acquired a new stake in Avalo Therapeutics in the fourth quarter valued at approximately $3,557,000. Finally, Millennium Management LLC grew its stake in shares of Avalo Therapeutics by 380.2% during the fourth quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock worth $11,985,000 after buying an additional 522,548 shares during the last quarter. 87.06% of the stock is currently owned by institutional investors and hedge funds.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.